BioRegenx, Inc.
BRGX
$0.01
-$0.0039-28.06%
OTC PK
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 33.20% | 98.55% | -4,559.56% | 64.30% | 64.91% |
| Total Depreciation and Amortization | 201.61% | -97.84% | 0.00% | 0.84% | 13.83% |
| Total Amortization of Deferred Charges | -180.00% | -89.51% | 66.28% | -36.76% | 21.43% |
| Total Other Non-Cash Items | 3.40% | -99.48% | 6,879.58% | -208.23% | -89.50% |
| Change in Net Operating Assets | -74.46% | 42.77% | 239.66% | -60.78% | -57.24% |
| Cash from Operations | -91.51% | 430.70% | 63.46% | 82.40% | -69.99% |
| Capital Expenditure | -- | -- | -- | -- | 100.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -100.00% |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | 100.00% |
| Cash from Investing | -- | -- | -- | -- | 100.00% |
| Total Debt Issued | -- | -- | -97.36% | -57.00% | -55.97% |
| Total Debt Repaid | -26.92% | -22.35% | 17.48% | 14.17% | 31.03% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 261.54% | -50.72% | -114.87% | -61.37% | -57.50% |
| Foreign Exchange rate Adjustments | -242.86% | -152.50% | 253.85% | -620.00% | -50.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -247.62% | 315.38% | -192.13% | 122.36% | -407.14% |